Louise Francesconi - Jan 23, 2024 Form 4 Insider Report for Accelerate Diagnostics, Inc (AXDX)

Role
Director
Signature
/s/ David Patience, attorney-in-fact
Stock symbol
AXDX
Transactions as of
Jan 23, 2024
Transactions value $
$0
Form type
4
Date filed
1/25/2024, 04:11 PM
Previous filing
Jun 29, 2023
Next filing
May 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXDX Common Stock Purchase +13.3K +175.57% 20.9K Jan 23, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXDX Common Stock Warrants (right to buy) Purchase +13.3K 13.3K Jan 23, 2024 Common Stock 13.3K $1.65 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities are included within 13,333 units of the issuer (the "Units") purchased by the reporting person for $1.50 per Unit in an underwritten public offering. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock.

Remarks:

On July 11, 2023, the issuer effected a reverse stock split of its common stock at a ratio of 1-for-10 (the "Reverse Stock Split"). As a result of the Reverse Stock Split, proportionate adjustments were made to the number of shares of the issuer's common stock underlying its outstanding equity awards, warrants and convertible notes, as well as the exercise or conversion price, as applicable. The amounts reported herein (and to be reported in subsequent reports) have been adjusted to reflect the Reverse Stock Split.